MedTrace Logo

Investigating the Pharmacokinetics of Petrelintide Using Different Drug Product Concentrations

NCT07338214 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2026-04-08

No results posted yet for this study

Summary

This clinical research study is testing the study compound petrelintide that is being developed for the weight management in people with obesity or overweight with co-morbidities or related diseases.

The goal is to learn how the same single dose of petrelintide, given using different concentrations, works in the body when given to participants with a BMI at, or above, 27kg/m2.

The main questions it aims to answer are:

1. Are there differences in how the body absorbs, distributes, metabolises and excretes petrelintide when same single dose petrelintide is given using different concentrations?
2. Are there differences in safety of petrelintide when same single dose petrelintide is given using different concentrations?

Participants will:

Visit the study center 10 times for tests and blood sampling (9 day ambulatory visits and 1 in-house visit of 4 consecutive days with sleeping 3 nights at the study center).

Petrelintide will be given once as a single injection in a skin fold of the abdomen on Day 1. The participants will be monitored until approximately Day 50.

Conditions

  • Obesity & Overweight

Interventions

DRUG

Petrelintide

Solution administered with a syringe

Sponsors & Collaborators

  • ICON Clinical Research

    collaborator INDUSTRY

  • Zealand Pharma

    lead INDUSTRY

Principal Investigators

  • Martha Haidacher · Charité Research Organisation GmbH

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-12-17
Primary Completion
2026-03-31
Completion
2026-03-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07338214 on ClinicalTrials.gov